(See all James M. Burns' publications in PubMed.)
"Evaluation of a Plasmodium-Specific Carrier Protein to Enhance Production of Recombinant Pfs25, a Leading Transmission-Blocking Vaccine Candidate"
Parzych EM, Miura K, Ramanathan A, Long CA, Burns JM Jr.
Infection and Immunity 86:e00486-17, 2018
"Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys"
Burns JM Jr, Miura K, Sullivan J, Long CA, Barnwell JW
Malaria J. 15:159. 2016
"Host erythrocyte environment influences the localization of exported protein 2, an essential component of the Plasmodium translocon"
Meibalan E, Comunale MA, Lopez AM, Bergman LW, Mehta A, Vaidya AB, Burns JM Jr.
Eukaryotic Cell. 14:371-384, 2015
"A chimeric Plasmodium falciparum merozoite surface protein vaccine induces high titers of parasite growth inhibitory antibodies"
Alaro JR, Partridge A, Miura K, Diouf A, Lopez AM, Angov E, Long CA, Burns JM Jr.
Infection and Immunity Immun. 81:3843-3854, 2013
"Remarkable stability in patterns of blood-stage gene expression during episodes of non-lethal Plasmodium yoelii malaria"
Cernetich-Ott A, Daly TM, Vaidya AB, Bergman LW, and JM Burns Jr.
Malaria J., in press. 2012
"Evaluation of the immunogenicity and vaccine potential of recombinant Plasmodium falciparum merozoite surface protein 8"
Alaro JR, Angov E, Lopez AM, Zhou H, Long CA, and JM Burns Jr.
Infect. Immun., 80: 2473-2484, 2012
Protective immune responses elicited by immunization with a chimeric blood-stage malaria vaccine persist but are not boosted by Plasmodium yoelii challenge infection
Alaro JA, Lynch MM and JM Burns Jr.
Vaccine, 28: 6876-6884, 2010
Elevated levels of the Plasmodium yoelii homologue of macrophage migration inhibitory factor reduce the severity of blood-stage malaria
Thorat, S, Daly TM, Bergman LW, and JM Burns Jr.
Infection and Immunity, 78: 5151-5162, 2010
Prediction of merozoite surface protein 1 and apical membrane antigen 1 vaccine efficacy against Plasmodium chabaudi malaria based on prechallenge antibody responses
Lynch, MM, Cernetich-Ott A, Weidanz WP and JM Burns Jr.
Clinical and Vaccine Immunology, 16:293-302, 2009
Suppression of lethal Plasmodium yoelii malaria following protective immunization requires antibody-, IL-4-, and IFN-γ-dependent responses induced by vaccination and/or challenge infection
Petritus PM and JM Burns Jr.
The Journal of Immunology, 180: 444, 2008
Enhanced protection against malaria by a chimeric merozoite surface protein vaccine
Shi Q, Lynch MM, Romero M, and JM Burns Jr.
Infection and Immunity, 75: 1349, 2007
Alteration in host cell tropism limits the efficacy of immunization with a surface protein of malaria merozoites
Shi Q, Cernetich A, Daly TM, Galvan G, Vaidya AB, Bergman LW, and JM Burns Jr.
Infection and Immunity, 73: 6363, 2005
Protection against Plasmodium chabaudi malaria induced by immunization with apical membrane antigen-1 and merozoite surface protein-1 does not require IFN-γ or IL-4
Burns Jr. JM, Flaherty JM, Nanavati P, and WP Weidanz
Infection and Immunity, 72: 5605, 2004
Immunization against Plasmodium chabaudi malaria using combined formulations of apical membrane antigen-1 and merozoite surface protein-1
Burns Jr., JM, Flaherty PR, and WP Weidanz
Vaccine, 21: 1843, 2003
A protective GPI-anchored membrane protein of Plasmodium yoelii trophozoites and merozoites contains two epidermal growth factor-like domains
Burns Jr., JM, Belk CC, and PD Dunn.
Infection and Immunity, Vol. 68, No. 11, November 2000